Zusammengesetzter Bewertungsbereich · konservativ ¥34–¥36 / fair ¥45–¥55 / optimistisch ¥64–¥68. Bei ¥48.42, Innerhalb des fairen Bereichs des inneren Werts.
Bei Veröffentlichung ¥50.04 (26. Juni 2026)
NMPA approved cyclosporine eye drops IV, described by Hengrui as China’s first 0.1% anhydrous cyclosporine eye drop.
Possible impact:May affect expectations for the ophthalmology pipeline and non-oncology revenue mix.
NMPA approved adebrelimab for perioperative treatment of resectable stage II-IIIB NSCLC.
Possible impact:May affect expectations for PD-L1 sales ramp and lung cancer franchise competitiveness.
EMA accepted Hengrui’s MAA for rezvilutamide in high-volume mHSPC, its first EU filing for a self-developed innovative drug.
Possible impact:May affect expectations for global expansion, while review outcome remains uncertain.
Hengrui and BMS agreed to advance 13 early-stage programs, with up to $950 million in payments and about $15.2 billion potential value.
Possible impact:May affect expectations for licensing income, pipeline globalization, and platform value.
Q1 revenue rose 12.98% to RMB 8.141 billion; net profit attributable to shareholders rose 21.78% to RMB 2.282 billion.
Possible impact:May affect expectations for innovative drug growth, profit leverage, and full-year performance.
Automatically summarized from public sources; for context only, not investment advice.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.